Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
MNPR - Monopar Therapeutics Inc.
Market Cap 9.76M P/E - EPS this Y 36.10% Ern Qtrly Grth -
Income -7.12M Forward P/E -1.64 EPS next Y -27.20% 50D Avg Chg -14.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -63.00%
Dividend N/A Price/Book 1.09 EPS next 5Y - 52W High Chg -85.00%
Recommedations 2.00 Quick Ratio 6.53 Shares Outstanding 3.52M 52W Low Chg 10.00%
Insider Own 53.29% ROA -53.45% Shares Float 1.64M Beta 1.16
Inst Own 2.38% ROE -102.31% Shares Shorted/Prior 652.49K/29.81K Price 0.74
Gross Margin - Profit Margin - Avg. Volume 390,070 Target Price 18.00
Oper. Margin - Earnings Date Nov 7 Volume 54,493 Change 1.79%
Healthcare | Biotechnology | United States
About Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.

Monopar Therapeutics Inc. News
12/20/24 Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
12/05/24 Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
12/03/24 Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
11/08/24 Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
10/30/24 Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
10/28/24 Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
10/28/24 Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
10/26/24 Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week
10/25/24 Monopar Therapeutics Secures License for Wilson Disease Treatment
10/24/24 Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
10/22/24 Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
10/16/24 Monopar Therapeutics Expands Portfolio with New Patent Filing
10/15/24 Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
10/08/24 Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial
10/07/24 Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
09/12/24 Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
09/04/24 Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
08/27/24 Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
07:00 AM Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
08/14/24 Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Cittadine Andrew Chief Operating Offi.. Chief Operating Officer Nov 14 Buy 3.08 16,053 49,443 24,238 11/16/22